Physician profile
Robert Michael Murray
NPI 1790892602
$4,242.27
in general payments reported to CMS, 2019-2025
29 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $1,875 · 2022: $186 · 2023: $287 · 2024: $361 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $464.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $402.68 | 2019-2025 | |
| Novo Nordisk INC | $391.22 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $370.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $369.79 | 2019-2025 | Breztri |
| Janssen Pharmaceuticals, INC | $364.21 | 2019-2020 | |
| Allergan, INC. | $248.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.50 | 2019-2020 | |
| Amarin Pharma, INC. | $199.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $195.77 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $145.08 | 2019-2025 | Kisunla |
| Astellas Pharma US INC | $125.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $123.06 | 2019 | |
| Esperion Therapeutics, INC. | $72.99 | 2020 | |
| Eisai INC. | $68.33 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.30 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $63.71 | 2019-2020 | |
| Medtronic, INC. | $46.53 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.60 | 2019-2020 | |
| Aytu Biopharma, INC. | $36.79 | 2020 | |
| Paratek Pharmaceuticals, INC. | $30.58 | 2024-2025 | Nuzyra, Xhance |
| Radius Health, INC. | $30.15 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.26 | 2020 | |
| Abbott Laboratories | $23.73 | 2022 | |
| Sanofi Pasteur INC. | $21.14 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.82 | 2020 | |
| Pulmonx Corporation | $14.60 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Ironwood Pharmaceuticals, INC | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.